Silvia Ghezzi

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes

Silvano Sozzani, Silvia Ghezzi, Gioacchin Iannolo et al. · The Journal of Experimental Medicine · 1998 · 232 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Fatty acid composition of plasma, blood cells and whole blood: Relevance for the assessment of the fatty acid status in humans

Patrizia Risé, Sonia Eligini, Silvia Ghezzi et al. · Prostaglandins Leukotrienes and Essential Fatty Acids · 2007 · 190 citations

Life Sciences, Nutritional Sciences, Physiology +17

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Andrea Sartore‐Bianchi, Sara Lonardi, Cosimo Martino et al. · ESMO Open · 2020 · 181 citations · Full text

Medicine, Oncology, Pharmacology +15

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu et al. · The Oncologist · 2019 · 169 citations · Full text

Medicine, Molecular Medicine, Oncology +17